AKT1 and breast carcinoma: (2) Heterogeneous subtype-specific evolution: For hormone receptor-positive (HR+) breast cancer, sustained PI3K/AKT activation driven by the relative dominance of estrogen disrupts normal glycosylation, leading to the cytoplasmic retention of NIS.